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charge. Scenario 1 represented a valuation of inhaled ver-
sus intravenous induction and scenario 2 represented a
valuation of inhaled versus intravenous maintenance. An
open-ended question was directed to test understanding
of the exercise, and thus validity of the valuation given. A
thematic framework approach was used to analyze these
qualitative data. A second researcher checked the consis-
tency of the coding of the themes in a sub-sample of the
statements (inter-rater reliability).
RESULTS: 260 (81%) parents/guardians and 907 (85%)
adults recruited onto the RCT were telephoned around
day seven. 88% and 85% of parents/guardians’ and
adults’ responses were classed as valid, respectively. 69%
of adults preferred an injection for induction (mean CV:
£237, SD: £370) and 31% preferred a mask (mean CV:
£144, SD: £110, p  .05). 97% of adults selected the sce-
nario with a lower nausea and vomiting rate (mean CV:
£192, SD: £149). 57% of parent/guardians preferred a
mask for induction (mean CV: £255, SD: £259) and 43%
preferred an injection (mean CV: £221, SD: £177, ns).
99% of parents/guardians selected the scenario with a
lower nausea and vomiting rate (mean CV: £238, SD:
£194).
CONCLUSION: Contingent valuation was used success-
fully in this prospective study. Telephone interviewing
produced a high response rate and respondent under-
standing of the exercise was high.
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OBJECTIVE: Quality of life (QoL) is a key parameter in
describing the impact of Systemic Lupus Erythematosus
(SLE). The reliability and validity of the Hungarian ver-
sion of the SLEQoL were assessed with the intention of
using it in clinical and health economic trials and burden-
of-disease studies in Hungary.
METHODS: Data were collected through a postal survey
of patients with SLE. Participants completed the SLEQoL
and Nottingham Health Profile (NHP) on two occasions,
two weeks apart. Test-retest reliability was assessed by
correlating SLEQoL scores at the two time points. Inter-
nal consistency was assessed using Cronbach’s alpha co-
efficients. Evidence of construct validity was gained by
correlating SLEQoL scores with NHP section scores and
by testing whether the measure was able to distinguish
groups that differed according to self-perceived severity
of condition.
RESULTS: Fifty-three patients participated in the survey.
Mean age of the sample was 39.9 years (SD  12.2), 49
patients (92.5%) were female and mean disease duration
was 12.0 years (SD  8.2). Test-retest reliability for pa-
tients who had no change in their condition between ad-
ministrations was 0.94. Cronbach’s alpha coefficients
were 0.90 and 0.93 at times 1 and 2 respectively. The
highest correlation was observed with the emotional re-
actions section of NHP and the lowest with pain and
sleep disturbance. Patients who perceived the severity of
their condition to be moderate or quite severe obtained
higher SLEQoL scores (indicating poorer QoL) than
those who perceived their condition to be mild (p  .05).
CONCLUSION: The Hungarian SLEQoL was shown to
have good test-retest reliability, indicating that it pro-
duces little random measurement error. Evidence of va-
lidity was also good. The results provide preliminary evi-
dence that the instrument will be able to detect changes
in QoL occurring in routine clinical practice or in clinical
trials or studies.
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OBJECTIVES: To date, surgical interventions in people
with haemophilia and high-titre, high-responding inhibi-
tors have been largely restricted to life-threatening situa-
tions. This is to the detriment of patients who would ben-
efit from surgery in terms of reduced pain, a reduction in
the frequency of regular bleeding episodes and improved
quality of life. However, with the development of recom-
binant FVIIa (rFVIIa: Novo Nordisk Ltd) elective surgery
such as joint replacement can be carried out safely with
effective haemostasis. This study examines the cost-con-
sequences of surgical intervention in this patient group
over time, to establish an estimate of the net cost of sur-
gery.
METHODS: A modeling framework has been used to es-
timate costs associated with haemostasis (rFVIIa treat-
ment) in patients for nine surgical procedures, and to
consider the cost-consequences of the intervention over a
five-year time horizon. Key parameters in the model have
been obtained from available literature (i.e. assumption
of reduction in bleeding episodes) and expert opinion
from a leading Haemophilia Comprehensive Care Centre
(i.e., protocols for haemostasis required during ortho-
paedic surgery, physiotherapy and rehabilitation).
RESULTS: For a typical person with haemophilia with
inhibitors, weighing 75kg, experiencing one regular bleed
per month in the affected joint, the costs for haemostasis
associated with total hip replacement are an estimated
£322,911. However, the net cost, when considering the
reduced costs of treatment for regular minor bleeds over
the following 5 years, are £298,401 (cost-saving) when
treating first line with rFVIIa.
CONCLUSIONS: In addition to improved quality of life,
orthopaedic surgery in people with haemophilia and in-
hibitors may be cost-saving when the reduction in regular
